The development of transgenic mouse models of mutant HSPB1 neuropathy and the encouraging preclinical studies of HDAC6 inhibitors in HSPB1 and GARS neuropathy have highlighted the need for robust natural history with which to guide future trial design. This evidence concerns the gene HDAC6 and neuropathy.